ReviewTherapeutics and clinical risk management2019
Unmet needs in asthma.
Review in Therapeutics and clinical risk management, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Article
- Article
- Maternal asthma imprints fetal lung ILC2s via glucocorticoid signaling leading to worsened allergic airway inflammation in murine adult offspring.Nature communications · 2025Article
- Tackling Comprehensive Asthma Education for Providers One Breath at a Time: Evaluation of an Online Continuing Medical Education Program for Asthma.CHEST pulmonary · 2024Article
- Article
- Unraveling the link between PTBP1 and severe asthma through machine learning and association rule mining method.Scientific reports · 2023Article
- A recombinant Der p 1-specific allergen-toxin demonstrates superior killing of allergen-reactive IgGImmunotherapy advances · 2023Article
- Characteristics of Severe Non-Eosinophilic Asthma: Analysis of Data from 1075 Patients Included in the FASE-CPHG Study.Journal of asthma and allergy · 2023Article
- Burden and unmet needs in asthma care in the Asia-Pacific region.Public health challenges · 2022Article
- Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged ≥4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study.BMJ open respiratory research · 2021Article
- Pharmacogenetic Polygenic Risk Score for Bronchodilator Response in Children and Adolescents with Asthma: Proof-of-Concept.Journal of personalized medicine · 2021Article
- Interferon characterization associates with asthma and is a potential biomarker of predictive diagnosis.Bioscience reports · 2021Article
- Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population.BMJ open respiratory research · 2021Article
- Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management.NPJ primary care respiratory medicine · 2020Review
- Expression of SMARCD1 interacts with age in association with asthma control on inhaled corticosteroid therapy.Respiratory research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite advances in the diagnosis and management of asthma, uncontrolled disease is still associated with a substantial mortality and morbidity burden. Patients often overestimate their level of asthma control while also reporting that asthma symptoms affect their quality of life and ability to work or study. There is some evidence of success with primary prevention measures in high-risk children and the secondary prevention of asthma in sensitized individuals or those at risk of developing occupational asthma. There are challenges with diagnosis - with under- and overdiagnosis and misdiagnosis being common - and in the treatment of asthma, despite clear treatment guidelines. In particular, severe asthma presents a huge challenge to the clinician, and its complex and heterogeneous nature warrants a personalized medicine approach to match therapies to individual patients. However, the tools for this are currently lacking in primary care. This article reviews the current unmet need in the diagnosis and clinical management of asthma, and provides an overview of the limitations of current therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.